<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02160899</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 494372-CS3</org_study_id>
    <nct_id>NCT02160899</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Patients With High Lipoprotein(a)</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of
      ISIS-APO(a)Rx given to patients with high lipoprotein(a) for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lipoprotein(a) [Lp(a)] is a genetic variant of low-density lipoprotein (LDL) in which the
      apolipoprotein B (apoB) -100 component of LDL is linked by a disulfide bond to
      apolipoprotein(a) [apo(a)], the distinct protein component of Lp(a) that is mainly
      responsible for its signature structural and functional properties. Lp(a) is now recognized
      as an important genetic risk factor for coronary artery disease, stroke and aortic stenosis.

      The purpose of this study is to determine if ISIS-APO(a)Rx can reduce the production of
      apolipoprotein(a), or apo(a). This study will enroll 50 patients with Lipoprotein(a) ≥50 and
      &lt;175 mg/dL and 10 patients with Lipoprotein(a) ≥175 mg/dL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of ISIS 494372 will be assessed by determining the incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters.</measure>
    <time_frame>Weekly for 32 weeks</time_frame>
    <description>To characterize the safety of ISIS-APO(a)Rx in individual patients at escalating doses of 100, 200, and 300 mg/week.
Results in patients dosed with ISIS 494372 will be compared with those from patients dosed with placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The tolerability of ISIS 494372 will be assessed by determining the incidence, severity, and dose-relationship of adverse effects and changes in the laboratory parameters.</measure>
    <time_frame>Weekly for 32 weeks</time_frame>
    <description>To characterize the tolerability of ISIS-APO(a)Rx in individual patients at escalating doses of 100, 200, and 300 mg/week.
Results in patients dosed with ISIS 494372 will be compared with those from patients dosed with placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the efficacy of ISIS-APO(a)Rx, changes inserum Lp(a) levels will be assessed following SC administration of ISIS 494372 and compared to placebo.</measure>
    <time_frame>End of study at week 32</time_frame>
    <description>To characterize the efficacy of ISIS-APO(a)Rx in lowering Lp(a) using a dose titration study design</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects of ISIS-APO(a)Rx</measure>
    <time_frame>End of study at week 32</time_frame>
    <description>To determine the pharmacodynamic effects of ISIS-APO(a)Rx, changes in levels of oxidized phospholipids associated with apoB-100, Lp-PLA2, lipoprotein(a) isoform size, lipid panel, systemic markers of inflammation, and plasminogen/coagulation markers will be assessed following SC administration of ISIS 494372 and compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Elevated Lipoprotein(a)</condition>
  <arm_group>
    <arm_group_label>ISIS-APO(a)Rx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: ISIS-APO(a)Rx Once-weekly dose administered subcutaneously of ISIS-APO(a)Rx from Day 1 to Day 78. Patients will receive 100 mg of ISIS-APO(a)Rx on Days 1, 8, 15, 22. Patients will receive 200 mg of ISIS-APO(a)Rx on Days 29, 36, 43, 50 unless down titrated. Patients will then receive 300 mg of ISIS-APO(a)Rx on Days 57, 64, 71, 78 unless down titrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo (Normal Saline) Once-weekly dose administered subcutaneously of Placebo from Day 1 to Day 78. Patients will receive 100 mg Placebo on Days 1, 8, 15, 22. Patients will receive 200 mg Placebo on Days 29, 36, 43, 50 unless down titrated. Patients will then receive 300 mg Placebo on Days 57, 64, 71, 78 unless down titrated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS-APO(a)Rx</intervention_name>
    <arm_group_label>ISIS-APO(a)Rx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (Normal Saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 18-65 inclusive

          -  Females must be non-pregnant and non-lactating, and either surgically sterile (e.g.,
             tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or
             post-menopausal (defined as 12 months of spontaneous amenorrhea without an alternative
             medical cause and FSH levels in the postmenopausal range for the laboratory involved)

          -  Males must be surgically sterile, abstinent or if engaged in sexual relations with a
             female of child-bearing potential, the patient must be using an acceptable
             contraceptive method from the time of signing the informed consent form until at least
             16 weeks after the last dose of Study Drug

          -  BMI ≤40 kg/m2

          -  Lipoprotein(a) ≥50 and &lt;175 mg/dL at time of screening (Cohort A)

          -  Lipoprotein(a) ≥175 mg/dL at time of screening (Cohort B)

        Exclusion Criteria:

          -  Clinically significant abnormalities in medical history (e.g., documented previous
             myocardial infarction, PCI, or major surgery within 3 months of screening, planned
             surgery that would occur during the study) or physical examination at screening

          -  Clinically significant abnormalities in screening laboratory values that would render
             a patient unsuitable for inclusion

          -  Active infection requiring systemic antiviral or antimicrobial therapy that will not
             be completed prior to Study Day 1

          -  Known history or positive test for human immunodeficiency virus (HIV), hepatitis C, or
             chronic hepatitis B

          -  Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix that has been successfully treated

          -  History of bleeding diathesis or coagulopathy

          -  Recent history of, or current drug or alcohol abuse

          -  Patients with Lp(a) ≥50 and &lt;175 mg/dL may not receive concomitant niacin therapy
             during the period 8 weeks prior to screening through the end of the Post-Treatment
             Evaluation Period

          -  Use of statins, ezetimibe or fibrates unless on a stable regimen for at least 8 weeks
             prior to dosing and will remain on a stable regimen for the duration of the study

          -  Use of lipid or Lp(a)-specific apheresis within 4 weeks prior to Screening through the
             end of the Post-Treatment Evaluation Period

          -  Use of concomitant drugs (including herbal or OTC medications other than ibuprofen,
             Benadryl or topical steroids) unless authorized by the Sponsor Medical Monitor

          -  Blood donation of 50-499 mL within 30 days of screening or of &gt;499 mL within 8 weeks
             of screening

          -  Have any other conditions, which, in the opinion of the Investigator would make the
             patient unsuitable for inclusion, or could interfere with the patient participating in
             or completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Gaudet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ECOGENE-21 Clinical Trial Center - Chicoutimi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Bergeron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique des Maladies Lipidiques de Quebec Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Borge Nordestgaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioanna Gouni-Berthold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniklinik Koeln, Zentrum fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hartmut Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Muenster, KMT Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elisabeth Steinhagen-Thiessen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite - University Hospital Berlin - Campus Virchow - Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Berend Isermann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Otto-von Guericke Universitaet, Uniklinik Magdeburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A Liem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sint Franciscus Gasthuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank L.J. Visseren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Stroes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Amsterdam - Dept. of Vascular Medicine F4-109</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abraham Anthonie Kroon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dermot Neely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newcastle Upon Tyne Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Handrean Soran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barlow Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart of England NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niels Riksen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboudumc Nijmegen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chicoutimi Hospital</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Maladies Lipidiques de Quebec Inc.</name>
      <address>
        <city>Quebec</city>
        <zip>G1V4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - University Hospital Berlin - Campus Virchow - Hospital</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Koeln, Zentrum fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP)</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von Guericke Universitaet, Uniklinik Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Amsterdam - Dept. of Vascular Medicine F4-109</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barlow Medical Centre</name>
      <address>
        <city>Manchester</city>
        <zip>M20 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2014</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Lipoprotein(a)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

